Isogenica Ltd, a leader in the use of synthetic biology and in vitro display for the discovery and optimisation of novel biotherapeutics, announced today that Dr William (Bill) Eldridge has been promoted to Chief Scientific Officer.
Since joining Isogenica as Senior Director of Antibody Alliances in January 2020, Dr Eldridge has played a leading role in delivering Isogenica’s multi-target antibody discovery collaborations and in the securing of valuable new partnerships benefiting our businesses growth.
“Bill has been central in transforming our discovery operations and providing oversight on new initiatives that position Isogenica for further growth based on our expertise in single-domain antibody therapeutics,” said Emma Sceats, Chief Executive Officer of Isogenica.
“His knowledgeable and thoughtful leadership and people-first approach has been a great strength in guiding our company through the challenges of the COVID-19 pandemic. I am certain that Bill will continue this trajectory as Chief Scientific Officer and I look forward to working with him to build upon Isogenica’s success.”
Dr Bjoern Cochlovius, Chairman of Isogenica added, “Bill’s extensive experience in drug discovery and development, and his passion for translating science into effective new medicines for patients, make him well-suited for his new role at Isogenica.”
Before joining Isogenica, Dr Eldridge held numerous senior leadership roles at Cambridge Antibody Technology (now Astra Zeneca) and Cyclogenix, working in antibody, scaffold protein and peptide discovery and development, developing early candidates into leads for preclinical studies.
Dr Eldridge started his career at Pfizer after completing a Medical Research Council funded
PhD at the University of Kent.
“Having started my career at Isogenica it’s an honour to now serve the company as its Chief Scientific Officer” said Dr Eldridge. “Isogenica’s synthetic antibody libraries are opening up so many targets and new epitopes and creating new possibilities to intervene in disease biology. I’m excited to lead the company into its next phase, where our innovation will be focused to the creation of highly developable candidate therapeutic antibodies that our partners can accelerate into the clinic.”
Article sourced from: https://www.isogenica.com/wp-content/uploads/2021/05/2021-05-21-Press-Release-re-CSO-002.pdf
Published on: 20.05.21